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Abstract
Radioiodine (RAI) is becoming the preferred treating option for benign thyroid diseases. 
Hyperthyroidism is defined as hypermetabolic state caused by high levels of circulating 
thyroid hormones of the thyroid gland. The most common hyperthyroidism causes are 
Graves’ disease, toxic multinodular goitre, and solitary hyperfunctioning nodule, for 
which RAI can be preferred as a definitive treatment option. It is rapidly incorporated 
into the thyroid and with its beta emissions with a path length of 1–3 mm cause exten-
sive local tissue damage and necrosis. The thyroid gland is effectively ablated over a 
period of 8–18 weeks and can no more produce normal amount of thyroid hormones. 
It is an individualized therapy that can either be a first-line therapy, or an alternative 
therapy to neck surgery or to use of antithyroidal drugs after 1 year. For the optimal 
efficiency, before the RAI treatment, the patients should be extensively assessed and they 
also should be given clear information about the treatment, as well as written instruc-
tions for precautions to avoid irradiation exposure to other people. Moreover, after RAI 
treatment patients should have their regular follow-up. This chapter summarizes all the 
points for a RAI treatment.
Keywords: radioiodine treatment, hyperthyroidism, Graves’ disease, toxic multinodular 
goitre, benign thyroid diseases
1. Introduction
Radioiodine (RAI) has been used for over 70 years as a treatment for benign thyroid diseases [1]. 
Regarding massive amount of past data, RAI treatment is broadly accepted as a safe and effective 
treatment for benign thyroid diseases with low incidence of acute or chronic adverse effects.
Thyrotoxicosis is thyroid-induced hypermetabolism, either secondary to thyroid hormone 
release from an overactive or inflamed thyroid gland or introduced from an extra-thyroidal 
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source. A suppressed serum thyroid stimulating hormone (TSH) level, below 0.4 mU/L, con-
firms the diagnosis of hyperthyroidism, meaning the pathology is within the thyroid gland [2]. 
To differentiate the cause of hyperthyroidism, RAI uptake test can be performed and a thyroid 
scan can give additional information. Figure 1 shows the thyroid scans of the main causes of 
hyperthyroidism: Graves’ disease and toxic multinodular disease and solitary hyperfunction-
ing nodules.
The symptoms of hyperthyroidism are nonspecific such as tachycardia, tremor, nervousness, 
anxiety, heat intolerance, sweating, and weight loss.
Hyperthyroidism can be treated with antithyroid drugs (ATDs), RAI therapy, and surgery. 
The actual therapy selected varies on the characteristics of the patient and the underlying 
cause of hyperthyroidism.
The aim of RAI therapy in patients with hyperthyroidism is to achieve a nonhyperthyroidal 
status that is not responding to ATDs and also to reduce the size of the nodules and to decrease 
the symptoms related to hyperthyroidism and gland enlargement in patients with toxic nodular 
goiter.
This chapter includes RAI treatment for benign thyroid diseases, I131 information, adminis-
tration, effect mechanism, indications and contraindications, patient preparation, I131 dose 
selection and withdrawal of antithyroid drugs, lithium and recombinant human TSH usage 
under a seperate topic, named special conditions, precautions, advers effects and patient 
follow-up.
2. Iodine131
I131, known as sodium iodine, is the most commonly used radionuclide therapy and also the 
first radiopharmaceutical to be used for the treatment of the thyroid gland in benign thyroid 
diseases since the 1940s [1].
Figure 1. The thyroid scans examples of the main causes of hyperthyroidism. (A) Graves’ disease, (B) toxic multinodular 
disease, and (C) solitary hyperfunctioning nodule.
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The principle mechanism of RAI treatment depends on the destructive effect of the radioac-
tivity that is directed to the target tissue thorough “cross fire effect” in a continuous manner. 
RAI is a beta-emitting radionuclide with a physical half-life of 8.02 days, a principal gamma 
ray of 364 keV, and a principal beta particle with a maximum energy of 0.61 MeV, average 
energy of 0.192 MeV, and average range in the tissue of 0.4 mm. The principal gamma ray of 
364 keV enables imaging with a gamma camera.
Oral capsule or in liquid form is the most common way to administer to patients; however, it 
can also be administered intravenously. When it is swallowed, it is absorbed in the gastroin-
testinal tract from blood circulation and then it accumulates in the thyroid gland.
2.1. The effect mechanism
The sodium iodide symporter (NIS) is an intrinsic plasma membrane glycoprotein that mediates 
the active transport of iodide in the thyroid gland and also in some extrathyroidal tissues, like 
lactating breast, gastric mucosa, and salivary and lacrimal glands [3]. RAI uptake occurs across 
the basolateral membrane of thyroid follicular cells via an active transport process mediated by 
the NIS, like inorganic iodine.
NIS protein expression is revealed to be heterogeneous at the basolateral membrane of a 
minority of follicular cells in normal thyroid gland tissue [4]; it is increased in thyroid tis-
sue in acute Graves’ disease, consistent with the clinical observation of diffusely increased 
radioiodine uptake [5]. In toxic multinodular goiters (TMNG), heterogeneous NIS protein 
expression appears to be stronger than the normal thyroid gland and less than the Graves’ 
thyroid tissue [6].
RAI is rapidly concentrated by the follicular cells and accumulated in colloid cells after iodide 
organification. Beta particles emitted by RAI destroy the functioning thyroid tissue. Hence, 
cell function is inhibited and proliferation capacity is affected by destructing follicular thyroid 
cell. The severity of this effect is directly proportional to the given dose.
The main effect of RAI treatment causes an intense radiation thyroiditis that leads to apopto-
sis and necrosis of hyperactive/active follicular thyroid cells, glandular atrophy, and loss of 
the thyroid capacity to synthesize and decrease thyroid hormones [7].
3. Indications and contraindications
Mainly, RAI therapy indications in benign thyroid diseases include Graves’ disease, toxic 
multinodular goitre, solitary hyperfunctioning nodule, nontoxic multinodular goitre, goitre 
recurrence after surgery, and also amiodarone-induced hyperthyroidism with special pre-
cautions and ablation of residual thyroid tissue in case of malignant ophthalmopathy after 
surgery, but during an inactive state of the orbitopathy.
RAI therapy’s absolute contraindications are pregnancy and breastfeeding, and relative con-
traindications are incapable patients to comply with radiation safety precautions, uncon-
trolled hyperthyroidism, and active thyroid orbitopathy.
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3.1. Graves’ disease
Graves’ disease patients in iodine-sufficient areas are approximately 80% of patients with 
thyrotoxicosis or hyperthyroidism [8]. Graves’ disease, also known as toxic diffuse goiter, 
is an autoimmune disease characterized by elevated levels of TSH receptor antibodies with 
increased production of thyroid hormones. TSH receptor antibodies bind to the TSH receptor 
and stimulate it chronically, which results in thyroid gland function becoming autonomous 
and independent of TSH feedback.
In general, Graves’ disease therapeutic options are ATDs, RAI, and surgery. Thus, a thera-
peutic strategy should be individualized in patient considering several situations such as 
patient’s clinical characteristics, age, and life style of the patient. ATDs are the most common 
treatment especially in children, teenagers, and pregnant women and also ATDs should be 
used as a first-line therapy to have the patient in euthyroidal status before the choice of 
treatment.
Commonly, methimazole is the first option drug, although propylthiouracil may be adminis-
trated in rare cases. ATDs’ key adverse effects are rash, artralgy, agranulocytosis, and hepatitis. 
The usual ATDs administration should be for 6–18 months and time to initial improvements 
are 2–4 weeks. However, in about half of the patients relapse of hyperthyroidism may be 
experienced when the ATDs are withdrawn after a standard 1–2 years of therapy [9].
Surgery is usually preferred in cases of large goiters with compressive symptoms or during 
second trimester of pregnancy. However, hospitalization and surgery complications includ-
ing hypoparathyroidism and recurrent laryngeal nerve injury and also anesthesia complica-
tions can be practiced.
RAI treatment is increasingly preferred in Graves’ disease as first treatment and also after 
ATDs treatment or thyroid surgery in uncontrolled hyperthyroidism patients. Most patients 
are effectively treated with a single therapeutic dose of RAI. The symptoms of hyperthyroid-
ism are expected to improve within 3 weeks of therapy; yet, the therapeutic effect takes 3–6 
months because of the stored thyroid hormone to be released [10]. However, RAI therapy may 
not be effective in approximately 10% of patients [10]. In these patients, the repeat RAI treat-
ment can be administered and usually the administered repeat dose should be of similar or 
higher than the first dose of RAI.
3.2. Toxic nodular goiter
Toxic nodular goiter (TNG) is the second most common cause of hyperthyroidism, after 
Graves’ disease [11], which may be presented with toxic multinodular goiter (TMNG) also 
known as Plummer’s disease or solitary hyperfunctioning nodule, also known as toxic ade-
noma. Hyperthyroidism may occur in both presentations. TNG autonomously produces 
excess thyroid hormones, resulting in hyperthyroidism. TSH receptor mutations in TNG have 
been reported to be as high as 80%. Somatic activating mutations of the TSH receptor activate 
the cAMP pathway and cause clonal autonomous growth and hyperfunctioning of the thy-
roid follicular cells, which results in TNG.
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Toxic nodules are more resistant to RAI therapy than Graves’ disease [10]. Considering this 
fact, the administered therapeutic RAI dose is often increased by 50% compared to what 
would be given in Graves’ disease.
3.3. I131 induced hyperthyroidism
Excessive I131 exposure, usually following the use of I131 containing drugs such as amioda-
rone, expectorants, and contrast agents, is the main cause of I131-induced hyperthyroidism 
and can cause destructive thyroiditis. The symptoms are similar to autoimmune thyroiditis, 
but because of the long biologic half-life of amiodarone and its metabolites the symptoms, 
it lasts longer. High I131 may induce increased synthesis of thyroid hormone, known as 
Jod-Basedow, usually occurring in nodular thyroid glands and is more common in endemic 
goiter areas. It can be treated with ATDs and also combination of potassium perchlorate may 
help to decrease thyroidal iodine content. Persistent cases may be treated with RAI defini-
tively if the thyroid uptake is adequate, provided that the agent has been discontinued for 
sufficient time of up to 2 years (mean period of 6 months) for the excess iodine load to be 
eliminated [12].
4. Patient preparation
Radioiodine therapy for patients with thyroid disease requires close cooperation between 
the nuclear medicine physician and the endocrinologist. The assurance of adequate therapy 
conditions is the overall responsibility of the nuclear medicine physician.
Evaluation of the patient before RAI therapy should include previous treatment of the 
patient (e.g., use of ATDs, amiodarone, contrast media, other iodine-containing medication, 
and iodine-containing food) and laboratory testing, including free T4, free T3, and TSH [13]. 
Thyroid scan preferably with I123, otherwise with Tc-99m, may be acquired.
Before RAI therapy, RAI uptake test should be performed for the differential diagnosis of 
hyperthyroidism to determine the I131 usage by the thyroid gland, and the calculation of the 
treatment dose. Increased RAI uptake values in patients with hyperthyroidism shows that 
elevated thyroid hormones belong to hyperfunctioning thyroid gland [14].
The 24-hour thyroid uptake in Graves’ disease is generally high; on the other hand, it is 
often normal or mildly elevated in TNG. RAI uptake test level obtained at 24-hour should 
be greater than 20%. If this level is lower than 20%, other treatment methods should be con-
sidered [13].
Thyroid gland volume and intrathoracic thyroid extension assessment should be acquired by 
ultrasonography. In patients with large goiters, intrathoracic extension can be evaluated with 
thyroid scan with sternal notch marked, magnetic resonance imaging, or computed tomography. 
If the evaluation is held with radiocontrast computed tomography, it should be kept in mind 
that radiocontrast agents will reduce the radioiodine uptake for weeks to months and as such 
disabling radioiodine therapy during that time.
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The nodules larger than 1–1.5 cm with a suspicious ultrasonographic look with nonfunctioning 
cold scan appearance in the thyroid scan should be assessed by fine needle aspiration biopsy 
to rule out malignancy.
The status of eye disease should be examined in patients with Graves’ ophthalmopathy by an 
experienced ophthalmologist.
In patients with severe thyrotoxicosis with high risk of thyroid storm and elderly patients 
should be maintained in euthyroidism status with ATDs, preferably with methimazole.
And treatment of other comorbid diseases should be regulated.
Patients receiving more than 444 MBq of RAI for benign thyroid diseases have dose rates of 
0.02 mSv per hour at 1 meter and so precautions are imposed. They do not require isolation, 
but they have to be cautioned to avoid contact with children and pregnant women, to sleep 
alone, to flush the toilet two to three times after use, and use separate utensils for 2–4 days and 
the effects of time and distance on dose should be indicated.
All patients receiving RAI should be given clear information about the treatment as well as 
written instructions for relevant precautions to avoid exposing others to unnecessary irra-
diation after treatment. Female patients in child bearing age and during pregnancy must be 
excluded and these patients should be counseled to avoid pregnancy for 3–6 months and to 
use contraception for 4 months after therapy.
5. I131 dose selection
Generally, the dose of RAI depends on the gland size, RAI uptake test, and biologic half-life of 
RAI in the thyroid gland [15], which may widely differ; however, several methods have been 
experienced for selecting adequate dose of RAI therapy in patients with hyperfunctioning 
thyroid gland [10].
A standard dose of 185–555 MBq is often prescribed. Yet, large glands need a relatively higher 
therapeutic dose and patients with a high RAI uptake test results need a lower dose.
Another method is using a standard formula with gland size, the RAI uptake test, and the 
proposed administered I131 dose per gram of thyroid tissue. Thus, an individual therapy 
dose for each patient is calculated by using the following formula [10]:
  I131 administered dose =  Gram size of thyroid gland × 100 − 180 µCi/g    __________________________________________________________24 hour % RAI uptake (1)
Another approach is to calculate the MBq per gram dose. The patients with nodular goiters 
and patients with very large toxic diffuse goiters are often referred for repeated therapies. In 
this method, the referring physician often prefers the higher dose (4.44–6.66 MBq/g tissue) for 
a higher likelihood of success with a single therapeutic dose.
Moreover, a higher RAI dose requirement is needed in patients, with a 4-hour I131 uptake 
result exceeding the 24-hour I131 uptake result, suggesting the rapid iodine turnover [15, 16].
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6. Special conditions
6.1. Withdrawal of antithyroid drugs
ATDs are the initial treatment option for patients with hyperthyroidism. ATDs pretreatment 
diminishes thyroid hormone stores and therefore decreases the risk of thyrotoxicrisis and 
the aggravation of symptoms after RAI treatment, constituting a safe patient preparation for 
RAI treatment [17]. However, ATDs pretreatment may lead to undesirable effects, such as an 
increased risk of radioiodine failure and worsening of thyrotoxicosis after discontinuation for 
pretreatment of RAI [17, 18].
Even though some studies support that pretreatment of ATDs may reduce the effect of RAI 
treatment [19, 20], some studies claim that they have no obvious effect [21, 22]. This side effect 
of ATDs is the possible radioprotective effect that seems to depend on a sulphhydryl group 
contained in ATDs. On the other hand, ATDs such as methimazole and carbimazole, which do 
not possess sulphhydryl groups and may be, do not possess radioprotective effect either [23]. 
Thus, pretreatment with thiouracils has been shown to reduce the therapeutic effectiveness of 
RAI, but the usage of carbimazole or methimazole has not been observed with similar effect 
[24]. This negative impact on RAI treatment can be compensated by discontinuation of the 
medication before RAI administration if the patient can tolerate it. Pretreatment with propyl-
thiouracil (PTU) is stopped for at least 2–3 weeks (if possible 8 weeks) before RAI treatment 
is given due to radioprotective effect of PTU [13]. Owing to methimazole and carbimazole 
having no side effect on cure rate, these drugs are stopped a few days before planned RAI 
administration [25, 26]. Beta-adrenergic antagonists (usually propranolol) can be used as an 
alternative to control hyperthyroidism symptoms during ATDs withdrawal. After RAI admin-
istration, ATDs should be restarted from the same recommended dose before RAI treatment. 
ATDs do not have to be restarted in young patients or in patients with mild hyperthyroidism.
6.2. Lithium usage
Lithium can block RAI release from the thyroid but does not interfere with RAI uptake. In 
general, lithium pretreatment is not routinely recommended but its administration can be 
considered for 7 days if 24-hour RAI uptake test is less than 20% [27]. However, a randomized 
controlled trial has found no evidence of an effect of lithium on RAI therapy when it is given 
for a few days after RAI treatment. The authors commented as it may increase the efficiency of 
RAI, but this effect is unclear [28]. Another research showed that lithium treatment prevents 
the rise in serum thyroid hormones after withdrawal of ATDs for RAI therapy [29].
6.3. Recombinant human TSH (rhTSH)
Recombinant human TSH (rhTSH; Thyrogen, Genzyme Transgenics Corp.) is developed to 
provide TSH stimulation without withdrawal of thyroid hormones. The therapeutic effect 
of I131 in patients with nodular goiter depends to some extent on the RAI uptake. The main 
cause of a low RAI uptake in patients with TNG is normal or below normal serum TSH levels. 
In patients with nontoxic or TNG with low I131 uptake, the administration of rhTSH increases 
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RAI uptake significantly and retention in the thyroid gland and minimizes the radiation dose 
to the remainder of the body without increase in serum thyroid hormones levels [15, 30]. 
Besides, by stimulating I131 uptake in relatively cold areas, more than in relatively hot areas, 
a more homogeneous distribution of I131 within the thyroid gland is observed in patients 
with nodular goiter, after single low dose rhTSH administration [31].
For the optimization of rhTSH dose, different rhTSH doses have been utilized. A study showed 
that a dose of 0.01 mg rhTSH administered 24 hours before RAI increases 24-hour RAIU from 29 
to 51%, while 0.03 mg rhTSH increased 24-hour RAIU from 33 to 63% [32]. Another study pre-
sented that RAI treatment after the administration of a single, low dose of rhTSH in patients with 
nodular goiter resulted in thyroid volume reduction 1 year after treatment by 35% in the group 
pretreated with 0.01 mg rhTSH and by 41% in the group pretreated with 0.03 mg rhTSH [33].
The leading side effects in nodular goiter are sensation of thyroidal swelling, transient thyroid-
itis, and transient goiter volume enlargement, which may lead to a significant cervical com-
pression within the first month of treatment after the administration of 0.3 mg of rhTSH [34].
In the adjunct therapies with very small doses of rhTSH (0.03–0.1 mg) in patients with mul-
tinodular goiter, either they were euthyroid or hyperthyroid, few safety concerns have been 
observed [35, 36]. Currently, the adjunct therapy with rhTSH is not indicated in patients with 
TMNG because of the risk of exacerbating patient’s hyperthyroidism [37].
7. Precautions for RAI therapy
The RAI preparations have negligible content of 0.05–0.18 µg large stable I131, which is much 
lower than the average daily iodine intake [13]. Therefore, even patients with known I131 
sensitivity can be treated with RAI safely.
On the other hand, approximately 7 days following RAI administration, temporary increase 
in serum thyroid hormone levels may be expected. Hence, RAI is contraindicated in patients 
who has uncontrolled symptoms of hyperthyroidism or high levels of free T3. The eleva-
tion of thyroid hormones may trigger atrial fibrillation or heart failure, leading to thyroid 
storm. These patients should continue using ATDs and beta-blockers for symptomatic control. 
Likewise, beta-blockers need not be stopped before RAI treatment. But, if ATDs are contra-
indicated (e.g., due to agranulocytosis or posttherapy liver failure) and surgery cannot be 
performed due to symptoms of hyperthyroidism, RAI may be given under steroid treatment 
(usually hydrocortisone 50–100 mg i.v.) and beta-blockers [13].
Similarly, patients with large nodular goiters should be treated under steroid treatment to 
prevent RAI-induced swelling thyroid, which rarely aggravates airway obstruction.
7.1. Graves’ ophthalmopathy
Graves’ disease exophthalmos cannot be controlled by ATDs and RAI therapy [38]. Further-
more, RAI may cause progression of Graves’ ophthalmopathy. After RAI therapy, 15% of 
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the patients with Graves’ disease may acquire newly evolving Graves’ ophthalmopathy [39] 
and up to 39% of patients may experience worsening of the former ophthalmopathy within 6 
months [40].
The risk factors for progression of Graves’ ophthalmopathy are preexisting ophthalmopathy, 
smoking [41], high levels of pretreatment serumT3 and TSH receptor antibody and thyro-
tropin receptor antibody levels (>7.5 IU/L) [42], severity of hyperthyroidism, and post-RAI 
hypothyroidism [38, 43, 44].
Thus, all patients who will receive RAI treatment should first be maintained in euthyroid state 
with ATDs and should be advised to quit smoking because of the increased risk of evolving 
of ophthalmopathy in smokers after RAI therapy [45]. The use of ATDs does not seem to be 
associated with the developing or worsening of preexisting ophthalmopathy in patients with 
Graves’ disease [46]. In patients with active ophthalmopathy, the risk can be reduced by a short 
cycle (3 months) of oral prednisone (0.3–0.5 mg/kg/d) started 1–3 days following RAI therapy 
and continued for 1 month, with tapering over the subsequent 2 months and by avoiding post-
RAI hypothyroidism with synthetic thyroid hormone placement [38, 43]. Despite the wide-
spread usage of steroid prophylaxis, its optimal schedule is undefined. The European Group 
on Graves’ Orbitopathy (EUGOGO) Consensus Statement on management of Graves’ oph-
thalmopathy suggested that a shorter term (about 2 months) of oral steroids treatment might 
be equally protective [38]. A recent retrospective cohort study suggested that starting from a 
few days after RAI therapy, 0.2 mg/kg/day of oral prednisolone for 6 weeks may be effective in 
preventing RAI-associated progression of Graves’ ophthalmopathy [47].
Patients with inactive Graves’ ophthalmopathy, if they do not have the risk factors for Graves’ 
ophthalmopathy, can have RAI therapy without steroid coverage as long as hypothyroidism 
is avoided [38].
8. Adverse effect of I131 therapy
The common acute side effects in the gastrointestinal tract are heartburn, nausea, diarrhea, 
and vomiting.
The acute adverse effects of RAI therapy include radiation-induced thyroiditis that is asso-
ciated with neck pain thyroid swelling and transient thyrotoxicosis. Thyroid swelling may 
appear after a few days following the therapy. The symptoms can be managed by nonsteroidal 
antiinflammatory drug. Early after RAI therapy, even though the goiter volume and the impact 
on the respiratory function remain unchanged [48], the critical thyroid swelling and respira-
tory distress can be experienced, fortunately it is a rare complication [49]. If the presence of tra-
cheal compression is previously known, especially in large goiter patients, 25 mg prednisolone 
may be given daily for 14 days to prevent thyroid swelling from RAI therapy [48].
Transient thyrotoxicosis, a transient elevation of the thyroid hormone levels, can be practiced 
due to the secretion of stored hormones from the thyroid gland. Thyroid storm or thyrotoxi-
crisis is a rare but severe and potentially life-threatening hypermetabolic condition induced 
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by excessive release of thyroid hormones. The treatment must include i.v. infusion of ATDs, 
steroids, and beta-blockers to avoid a fatal outcome.
Other side effects of RAI therapy include sialoadenitis leading to temporary or permanent 
salivary gland dysfunction and lacrimal canal obstruction, which can be demonstrated as 
RAI-induced acute histopathological changes as well. Hydration should be encouraged 
to minimize these problems. Sour candy can be suggested for salivary gland dysfunction. 
However, there are also studies demonstrating that permanent xerostomia is significantly 
more common in patients having sour candy in the first 24 hours of RAI therapy than in 
patients having the candy after the first day [50]. Consequently, several antioxidant agents are 
under evaluation to reduce these changes in many researches [51–53].
The main and long-term adverse effect of RAI therapy is the hypothyroidism. Usually in the 
first 2 years after RAI therapy, hypothyroidism occurs in up to 50% of patients and the risk 
increases in patients with small goiter size, positive TPO antibodies, and a family history 
of autoimmune thyroid disease [54]. Pretreatment of ATDs does not affect the frequency of 
hypothyroidism. Generally, it is very difficult to predict if the development of hypothyroid-
ism is either transient or permanent. In a few months after RAI therapy, if the level of serum 
TSH is still above 45 mU/L, transient hypothyroidism is ruled out [55]. A transient hypothy-
roidism develops a few months after RAI therapy and continues about 1–4 months and does 
not require thyroid hormones replacement. The patients should be offered annual follow-up 
testing of thyroid hormones.
Another adverse effect is the post-RAI autoimmune thyroiditis and immunogenic hyperthy-
roidism/Graves’ disease. About 1% of patients following RAI therapy of nodular goiter may 
develop Graves’ disease. This risk increases approximately 10-fold when TPO antibody lev-
els are elevated before RAI. The release of thyroid antigens and other immunogenic effects 
of RAI on thyroid-autoreactive lymphocytes are the presumed mechanisms. In addition, 
there is an estimated 1.3% risk of a temporary increase of TSH receptor antibodies after RAI 
for autonomous thyroid disease without the development of clinically apparent hyperthy-
roidism [56].
Finally, even though, the chromosomal damage in peripheral lymphocytes is induced after 
RAI therapy for benign thyroid diseases [57], the role of I131 in radiation-induced cancers 
remains unclear. There is no evidence of the risk of malignancy as a consequence of thyroid 
and whole-body irradiation. Though there is low risk of preexisting or coexisting thyroid 
cancer in patients with toxic nodular goiter and Graves’ disease unrelated to RAI therapy [58].
9. Results
The success of RAI therapy is defined as the elimination of hyperthyroidism, in which the 
patient may be either in euthyroid state or in hypothyroid state that is compensated by 
 synthetic thyroid hormone. The successful therapy rate depends on thyroid volume, compen-
sation of hyperthyroidism, I131 intake in the diet, the timing of the withdrawal of ATDs, and 
the dosage in the different thyroid diseases.
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The low fixed activity (185 MBq) of I131 seems to be effective in 73% of Indian patients with 
Graves’ disease, 1 year after RAI therapy [59]. Another study compared doses of 370 and 555 
MBq of RAI and the success rates at 12 months of both doses brought about a similar remis-
sion of the hyperthyroidism in patients with Graves’ disease [27, 60].
A study based on tissue-absorbed dose calculations demonstrated that the frequency of per-
sistent hyperthyroidism decreased to 27% after 150 Gy, to 23% after 200 Gy, and to 8% after 
300 Gy [61]. However, the possibility of occurrence of hypothyroidism increases over years 
and patients need to be in regular follow-up.
RAI therapy is more successful in patients with nodules smaller than 2 cm [62]. However, 
there is currently no consensus about the appropriate RAI dose in TNG, both the fixed dose 
or calculated dose can be given. Effect of fixed and calculated doses on hyperthyroidism was 
compared in a meta-analysis that reported both methods to be equally successful [63].
Zakavi et al. compared fixed low and fixed high RAI doses for treating a single toxic thyroid 
nodule in patients with no age, sex ratio, thyroid uptake, and thyroid weight differences. Ten 
months after RAI therapy, the success of hyperthyroidism treatment was higher in patients 
calculated with high dose therapy than other groups [64].
Glucocorticoids did not influence the final outcome following RAI [65]. At least 2 days of 
methimazole withdrawal was long enough to restore the success of RAI therapy [26].
10. Follow-up
After the RAI administration ATDs should be restarted after 3–5 days and withdrawn as soon 
as thyroid function normalizes and synthetic thyroid hormone replacement should be started 
as soon as hypothyroidism occurs [8].
Patients who have been given RAI therapy should be essentially followed up in regular 
review of thyroid function tests to evaluate the effectiveness of the treatment and for timely 
detection of developing hypothyroidism or posttreatment immunogenic hyperthyroid-
ism. Follow-up should be basically performed with TSH and serum T4 tests, 4–6 weeks 
after RAI treatment. The patients receiving ATDs or having increased risk of developing or 
worsening of Graves’ ophthalmopathy due to hypothyroidism, shorter intervals of the tests 
should be performed 2–3 weeks after RAI treatment is recommended [13]. All the patients 
should have annual laboratory tests, at least TSH levels should be checked regularly. In 
patients with relapse or persistent hyperthyroidism, RAI treatment can be repeated after 
6–12 months.
11. Conclusion
With over 7 decades of experience, RAI therapy is an individualized, safe, and effective treat-
ment modality, which is doubtlessly going to be still available in the future with possible up 
coming features in genetics.
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In several types of hyperthyroidism TSH receptor gene mutations may be expressed, for 
instance, familial gestational hyperthyroidism, autonomous toxic adenomas, hereditary or 
sporadic toxic thyroid hyperplasia, familial nonautoimmune hyperthyroidism, and Graves’ 
disease. Genetic studies focusing on the mutations of TSH receptor gene and their alterations 
with the related genes would probably open a new door in the understanding of the process 
and may support the prospective treatments.
In addition to safeguard the other tissues especially nonthyroidal NIS-expressing tissues, e.g., 
lactating breast, gastric mucosa, lacrimal glands, and salivary glands, for example, temporar-
ily opening tissue-specific NIS expression or downregulating the functional expression of NIS 
in different cellular models may certainly provide an optimal use by directly affecting the RAI 
dose received by the specific target tissue [66].
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